MAKING A POSITIVE IMPACT

Cell therapies offer the potential for single-dose cures of cancer. CTMC was created to bring together the leading complex biologics manufacturing technology organization and the leading clinical cancer center to enable innovation from academia and biotech to accelerate Cell Therapy’s impact for cancer patients.

Commercialization Mindset + Innovative Research

CTMC operates at the intersection of cutting-edge biopharmaceutical manufacturing technology of Resilience and cancer innovation at MD Anderson Cancer Center. By bringing together the commercial network of Resilience and access to MD Anderson’s leading cancer research capabilities, CTMC is a first-of-its-kind cell therapy engine. We aim to advance novel scientific breakthroughs into medicines developed rapidly and robustly to ultimately end cancer.

Industrial Manufacturing + Data-Rich Clinical Trials

Leveraging 60,000 sq. ft. purpose-built cell therapy development and industrial-grade cGMP cleanroom space with Resilience’s cloud-based, digital-first electronic systems, CTMC works hand in hand with MD Anderson’s clinic to coordinate all logistics of cell therapy manufacturing, infusion, patient care and clinical correlate analysis. This integrated approach gives novel, first-in-human therapies the best chance to declare their potential and demonstrate proof of principle in a patient-efficient manner.

CMC Quality by Design + Scientific-Depth

The CTMC team is comprised of industry veterans and former academic scientists enabling scientific depth applied to development of cell therapy processes and platforms. With an eye on commercialization, CTMC takes a rigorous approach to process and analytical development, by maintaining close relationships with the Resilience’s manufacturing technology development engineers, as well as MD Anderson’s key opinion leaders.